Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159056 | 0.97 | HDAC3 (0.55) | LMNAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL12333287 | 0.97 | HDAC3 (0.55) | LMNAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL29315161 | 0.97 | HDAC3 (0.55) | LMNAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5909483 | 0.97 | HDAC3 (0.55) | LMNAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5909431 | 0.97 | HDAC3 (0.55) | LMNAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5909180 | 0.93 | LMNA (0.57) | LMNAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7782849 | 0.89 | LMNA (0.58) | LMNAALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL12581893 | 0.89 | PAOX (0.48) | LMNAHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL806271 | 0.89 | — | — | |
| SCHEMBL103082 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2024072908-A1 | COMPOUNDS WITH CLEAVABLE DISULFIDE MOIETIES | REINVIGORON THERATECH, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11701864-B2 | Metal/resin composite structure and manufacturing method of metal/resin composite structure | MITSUI CHEMICALS, INC. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11701864-B2 | Metal/resin composite structure and manufacturing method of metal/resin composite structure | MITSUI CHEMICALS, INC. (JP) | 2023-07-18 | — | — | US | disclosed |
| EP-3157978-B1 | STRICTLY SEGMENTED THERMOPLASTIC ELASTOMERS AS BIODEGRADABLE BIOMATERIALS | SYMO CHEM B V (NL) | 2021-08-11 | — | — | EP | disclosed |
| US-20200254728-A1 | METAL/RESIN COMPOSITE STRUCTURE AND MANUFACTURING METHOD OF METAL/RESIN COMPOSITE STRUCTURE | MITSUI CHEMICALS, INC. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-10618866-B2 | Method for synthesising partially N-hydroxyethylated tertiary 1,6-hexanediamines | IFP Energies Nouvelles (FR) | 2020-04-14 | — | — | US | disclosed |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2017-07-27 | — | — | US | disclosed |
| US-9649279-B2 | Fortified micronutrient salt formulations | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-05-16 | — | — | US | disclosed |
| US-9096653-B2 | Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-08-04 | — | — | US | disclosed |
| US-9065138-B2 | Water soluble binder composition, method of producing the same and electrode for rechargeable battery employing the same | SAMSUNG SDI CO., LTD. (KR) | 2015-06-23 | — | — | US | disclosed |
| US-20130273423-A1 | WATER SOLUBLE BINDER COMPOSITION, METHOD OF PRODUCING THE SAME AND ELECTRODE FOR RECHARGEABLE BATTERY EMPLOYING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2013-10-17 | — | — | US | disclosed |
| US-20130216570-A1 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | The United States of America, as represented by he Secretary, Department of Health and Human | 2013-08-22 | — | — | US | disclosed |
| US-8444996-B2 | Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110182929-A1 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | NEW YORK UNIVERSITY | 2011-07-28 | — | — | US | disclosed |
| US-7795314-B2 | Protective role of semapimod in necrotizing enterocolitis | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070282005-A1 | HMGB1 EXPRESSION AND PROTECTIVE ROLE OF SEMAPIMOD IN NEC | FERRING BV (NL) | 2007-12-06 | — | — | US | disclosed |
| WO-2001058912-A1 | DINUCLEAR GROUP 4 METAL BORON OR ALUMINUM BRIDGE CONTAINING ANSA-COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 2001-08-16 | — | — | WO | disclosed |
| US-4142029-A | Bis-tetrazoles as chemical blowing agents for foaming thermoplastic resins | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216570-A1 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | CD47, NASP, CD69 | LMNA 4399/4885HDAC3 3289/4885HDAC1 4595/4885 |
| US-20110182929-A1 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | CD47, NASP, CD69 | LMNA 4399/4885HDAC3 3289/4885HDAC1 4595/4885 |
| US-20070282005-A1 | HMGB1 EXPRESSION AND PROTECTIVE ROLE OF SEMAPIMOD IN NEC | HMGB1, HMGB2, BAD | LMNA 1732/4885HDAC3 2154/4885HDAC1 1382/4885 |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | NHERF1, SLC9A3, SLC26A3 | LMNA 3991/4885HDAC3 69/4885HDAC1 273/4885 |
| US-10618866-B2 | Method for synthesising partially N-hydroxyethylated tertiary 1,6-hexanediamines | BHMT2, DNMT1, HNMT | LMNA 2195/4885HDAC3 1835/4885HDAC1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.